CCR

CC chemokine receptor (CCR) antagonists block G protein-coupled receptors that guide leukocyte migration. CCR2, a receptor for monocyte chemoattractant protein 1 (MCP-1), was cloned in 1994 as two splice variants. CCR5 was identified in 1996 as a fusion cofactor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1). Maraviroc, described in 2005 as a selective small-molecule CCR5 inhibitor, blocks this route of viral entry. Other CCR5 antagonists include vicriviroc malate and aplaviroc, while INCB3344 and MK-0812 target CCR2. Cenicriviroc blocks both CCR2 and CCR5, and GSK2239633A is a CCR4 antagonist for studies of T cell trafficking.

Items 101-125 of 154

  • DPC-168
    Cat. No.
    A59547

    DPC-168

    DPC-168 is a potent CCR3 antagonist with an IC50 of 41 nM. It demonstrates significant inhibition of eosinophil chemotaxis and is effective in reducing pulmonary inflammation. This compound is suitable for research applications targeting airway inflammation and related respiratory conditions.

    Out of stock

    All 3 sizes
  • YJC-10592
    Cat. No.
    A59548

    YJC-10592

    YJC-10592 is a potent orally active antagonist of the CCR-2 chemokine receptor. It selectively inhibits CCR-2 signaling, making it a valuable tool for investigating the role of this receptor in inflammatory processes. YJC-10592 is suitable for research applications related to asthma and idiopathic dermatitis, contributing to the understanding of disease mechanisms and potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • CCR5 antagonist 4
    Cat. No.
    A59550

    CCR5 antagonist 4

    CCR5 antagonist 4 is a potent oral antagonist of the CCR5 receptor. This compound exhibits significant biological activity by blocking CCR5-mediated signaling pathways, making it an important tool in the study of inflammatory diseases such as rheumatoid arthritis. Its application in research could provide insights into the modulation of immune responses and potential therapeutic strategies.

    Out of stock

    All 3 sizes
  • CCR1 antagonist 10
    Cat. No.
    A59552

    CCR1 antagonist 10

    CCR1 antagonist 10 is a potent and orally bioavailable antagonist of the CCR1 receptor. It effectively inhibits the binding of 125I-MIP-1α to THP-1 cell membranes, demonstrating a Ki value of 2.3 nM. This compound is valuable for research applications involving inflammation, immune response modulation, and related signaling pathways.

    25 mg
    $2,665.00
    50 mg
    $3,430.00
    All 3 sizes
  • LMD-902
    Cat. No.
    A59553

    LMD-902

    LMD-902 is a potent CCR8 agonist with an EC50 of 15 nM, demonstrating enhanced binding capacity influenced by critical residues such as PheVI:16. This compound is instrumental in researching inflammatory diseases, including bronchial asthma, as well as central nervous system disorders such as multiple sclerosis. Its specificity and efficacy make LMD-902 a valuable tool for advancing understanding in these therapeutic areas.

    Out of stock

    All 3 sizes
  • JNJ-17166864
    Cat. No.
    A59554

    JNJ-17166864

    JNJ-17166864 is a highly selective CCR2 antagonist that demonstrates significant potential in modulating inflammatory responses. This compound has shown efficacy in reducing alveolar bone loss in a mouse model of periodontitis induced by Porphyromonas gingivalis infection. JNJ-17166864 is useful for research applications focused on inflammatory diseases, including allergic rhinitis and periodontal conditions. Its selectivity and biological activity make it a valuable tool for understanding CCR2-mediated pathways in these disease models.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • LUF8100
    Cat. No.
    A59555

    LUF8100

    LUF8100 is a dual-target antagonist of CCR2 and CCR5, exhibiting pKi values of 5.23 for CCR2 and 4.97 for CCR5. This compound demonstrates significant potential in modulating immune responses and has relevance in cancer research, allowing for the investigation of immune homeostasis and potential therapeutic applications in pathologies driven by these chemokine receptors.

    Out of stock

    All 3 sizes
  • CXCR2/CCR7 antagonist-1
    Cat. No.
    A59556

    CXCR2/CCR7 antagonist-1

    CXCR2/CCR7 antagonist-1 is a potent dual antagonist of the chemokine receptors CXCR2 and CCR7, exhibiting IC50 values of 0.0046 μM and 0.0014 μM, respectively. This compound serves as a valuable tool in the investigation of cancer metastasis and the mechanisms underlying autoimmune diseases, facilitating the study of therapeutic strategies targeting these pathways. Its efficacy in inhibiting both receptors makes it suitable for a range of biochemical and pharmacological research applications.

    Out of stock

    All 3 sizes
  • CP-481715
    Cat. No.
    A59558

    CP-481715

    CP-481715 is a potent and selective antagonist of the CCR1 receptor, exhibiting a Kd of 9.2 nM for human CCR1. This compound demonstrates over 100-fold selectivity for CCR1 compared to a wide array of G-protein-coupled receptors, including related chemokine receptors. CP-481715 is primarily utilized in research related to rheumatoid arthritis and various inflammatory diseases, making it a valuable tool for investigating immune responses and therapeutic interventions in these conditions.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • GSK-2239633
    Cat. No.
    A59559

    GSK-2239633

    GSK-2239633 is a potent CCR4 antagonist that inhibits the chemokine receptor involved in the regulation of immune responses. This compound demonstrates significant biological activity in modulating T cell trafficking and has potential applications in asthma research and related inflammatory disorders. GSK-2239633 is valuable for studies focusing on immune modulation and therapeutic approaches for allergy and respiratory conditions.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • ALK4290 dihydrochloride
    Cat. No.
    A59560

    ALK4290 dihydrochloride

    Synonyms: AKST4290 dihydrochloride

    ALK4290 dihydrochloride is a potent inhibitor of the CCR3 receptor, exhibiting a Ki value of 3.2 nM for human CCR3. This compound demonstrates significant potential for modulating immune responses, making it a valuable tool in the study of neovascular age-related macular degeneration and Parkinson's disease. Researchers can utilize ALK4290 to investigate its effects on CCR3-related signaling pathways and its implications in various pathological conditions.

    25 mg
    $1,385.00
    50 mg
    $1,835.00
    All 3 sizes
  • ECL1i
    Cat. No.
    A59561

    ECL1i

    ECL1i is an allosteric inhibitor targeting the CCR2 receptor. It selectively disrupts CCL2/CCR2-mediated chemotaxis, thereby impeding the recruitment of CCR2-positive cells. ECL1i has demonstrated efficacy in attenuating disease progression in models of experimental autoimmune encephalomyelitis, making it a valuable tool for studying autoimmune disease mechanisms and potential therapeutic interventions.

    Out of stock

    All 3 sizes
  • CCR2-RA
    Cat. No.
    A59562

    CCR2-RA

    CCR2-RA is an allosteric antagonist of the chemokine (C-C motif) receptor 2 (CCR2). This compound selectively inhibits CCR2 signaling, making it a valuable tool in cancer research to explore the role of chemokine receptors in tumor progression and metastasis. Its application extends to investigating the modulation of immune responses in the tumor microenvironment.

    Out of stock

    All 3 sizes
  • (s)-PF-4136309
    Cat. No.
    A59563

    (s)-PF-4136309

    Synonyms: (s)-INCB8761

    (s)-PF-4136309 is the isomer of the CCR2 antagonist PF-4136309, serving as an effective experimental control in research settings. This compound exhibits high potency and selectivity, with IC50 values of 5.2 nM, 17 nM, and 13 nM for human, mouse, and rat CCR2, respectively. Its selective inhibition of CCR2 makes it valuable for studying inflammatory responses and related pathologies.

    5 mg
    $70.00
    10 mg
    $120.00
    All 5 sizes
  • BAY-3153
    Cat. No.
    A59566

    BAY-3153

    BAY-3153 is a selective antagonist of the C-C motif chemokine receptor 1 (CCR1), with human IC50 values of 3 nM, rat IC50 of 11 nM, and mouse IC50 of 81 nM. This compound serves as a valuable tool for investigating the role of CCR1 in various biological processes, including inflammation and immune response modulation. Its specificity and potency make it suitable for research applications involving chemokine signaling and receptor activity.

    1 mg
    $435.00
    5 mg
    $975.00
    All 5 sizes
  • SB-649701
    Cat. No.
    A59567

    SB-649701

    SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 of 7.7. This compound is primarily utilized in research related to asthma, providing insights into inflammatory pathways and the role of CCR8 in immune responses. Its mechanism of action makes it valuable for exploring therapeutic strategies targeting airway hyperreactivity and allergic conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • BMS-741672
    Cat. No.
    A59568

    BMS-741672

    BMS-741672 is a selective orally active antagonist of the CCR2 receptor, exhibiting an IC50 of 1.1 nM. This compound demonstrates over 700-fold selectivity for CCR2 compared to CCR5, making it a valuable tool for investigating the role of CCR2 in inflammatory processes. BMS-741672 has potential applications in studies of immune responses and related pathologies, contributing to the understanding of therapeutic strategies targeting chemokine signaling pathways.

    25 mg
    $2,665.00
    50 mg
    $3,430.00
    All 3 sizes
  • CH0076989
    Cat. No.
    A59570

    CH0076989

    CH0076989 is a selective agonist of the CCR3 receptor that activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimeric receptor lacking the CCR3 amino-terminus. This compound exhibits a direct interaction with the transmembrane helices of CCR3; activity is abolished by mutations of key residues Y41, Y113, and E287. CH0076989 is ideal for research into inflammation and allergic diseases, including asthma, making it a valuable tool for understanding these pathological conditions.

    25 mg
    $1,530.00
    All 1 sizes
  • RO5234444
    Cat. No.
    A59572

    RO5234444

    RO5234444 is an orally active CCR2 antagonist with an IC50 of 22 nM for human CCR2 and 161 nM for mouse CCR2. This compound demonstrates significant biological activity by alleviating glomerulosclerosis, reducing albuminuria, and improving glomerular filtration rate (GFR) in the uninephrectomized type 2 diabetic db/db mouse model. RO5234444 serves as an essential tool for the investigation of type 2 diabetic nephropathy.

    Out of stock

    All 3 sizes
  • YM-344031
    Cat. No.
    A59574

    YM-344031

    YM-344031 is a potent orally active antagonist targeting the CCR3 chemokine receptor. It effectively inhibits the binding of Eotaxin-1 and RANTES to CCR3 with IC50 values of 3.0 nM and 16.3 nM, respectively. This compound also reduces ligand-induced increases in intracellular calcium levels and chemotactic responses. Additionally, YM-344031 demonstrates the ability to ameliorate eotaxin-1-induced morphological changes in eosinophils from macaque blood and mitigates allergic skin responses in murine models, making it a valuable tool for research in allergic and inflammatory conditions.

    Out of stock

    All 3 sizes
  • CCR1 antagonist 12
    Cat. No.
    A59575

    CCR1 antagonist 12

    CCR1 antagonist 12 is a selective antagonist of the CCR1 receptor, exhibiting an IC50 of 3 nM for human CCR1. This compound effectively inhibits CCL3-induced transwell chemotaxis, with an IC50 of 0.009 µM, making it a valuable tool for studying chemokine-mediated signaling pathways. Additionally, CCR1 antagonist 12 demonstrates favorable pharmacokinetic properties in rat models, supporting its potential use in preclinical research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Maceneolignan H
    Cat. No.
    A59576

    Maceneolignan H

    Maceneolignan H is a selective CCR3 antagonist, with an EC50 value of 1.4 μM. Isolated from the arils of Myristica fragrans, this neolignane compound demonstrates significant potential in the study of allergic diseases. Its ability to inhibit CCR3 suggests applications in researching therapeutic strategies for conditions mediated by this receptor.

    Out of stock

    All 3 sizes
  • CCR2 ligand-1
    Cat. No.
    A59577

    CCR2 ligand-1

    CCR2 ligand-1 is a potent ligand for the chemokine receptor CCR2, playing a crucial role in mediating inflammatory responses. This compound is valuable for studying CCR2 signaling pathways and its implications in diseases such as cancer and rheumatoid arthritis. Additionally, CCR2 ligand-1 can be utilized in the synthesis of LUF7996 when conjugated with Linker PIN1 degrader-3 and E3 ligase ligand Thalidomide 4-fluoride, facilitating research in targeted protein degradation.

    Out of stock

    All 3 sizes
  • BMS-639623
    Cat. No.
    A59578

    BMS-639623

    BMS-639623 is a highly potent and orally bioavailable antagonist of the chemokine receptor CCR3, exhibiting an IC50 value of 0.3 nM. This compound demonstrates exceptional inhibitory activity against eosinophil chemotaxis, with an IC50 of 38 pM. BMS-639623 is primarily utilized in research focused on asthma and related inflammatory conditions.

    25 mg
    $1,780.00
    50 mg
    $2,280.00
    All 3 sizes
  • CCR3 antagonist 2
    Cat. No.
    A59579

    CCR3 antagonist 2

    CCR3 Antagonist 2 is a selective antagonist of the CCR3 receptor, a chemokine receptor involved in mediating inflammatory responses. This compound is particularly useful for research applications related to inflammatory and allergic conditions, including obstructive airways diseases. By interfering with CCR3 signaling, it allows for the exploration of therapeutic strategies aimed at modulating immune responses associated with these pathologies.

    Out of stock

    All 3 sizes

Items 101-125 of 154

Added to your cart

View Cart Checkout

    Loading...